Dr. Reddy's Laboratories Ltd (RDY)
RDY moved a median of 0.00% 30 minutes after news, and -0.15% by the close. How RDY actually reacts to news — the realized, point-in-time move the market made, measured across 528 labeled events over the last three years with zero look-ahead.
RDY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 518 |
| 30-min | 0.00% | 47% | 525 |
| 60-min | -0.04% | 45% | 525 |
| to close | -0.15% | 39% | 521 |
| Middle 50% of RDY reactions | -0.22% to +0.20% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 528 |
Half of all Dr. Reddy's Laboratories Ltd news events land between -0.22% and +0.20% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RDY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 16 | +0.03% | 63% | -0.14% |
| Analyst downgrades | 18 | +0.18% | 67% | +0.13% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how RDY ranks against every other measured name →
That’s how RDY usually reacts — get an email when it moves on news →Email me when RDY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RDY's baseline. Nothing else.
Recent RDY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K DR REDDYS LABORATORIES For: Oct 08 | SEC filing · Form 6-K | SEC EDGAR | +0.04% | +0.87% | |
| Form 6-K DR REDDYS LABORATORIES For: Oct 07 | SEC filing · Form 6-K | SEC EDGAR | -0.73% | -1.05% | |
| Form 6-K DR REDDYS LABORATORIES For: Oct 03 | SEC filing · Form 6-K | SEC EDGAR | +0.08% | +0.57% | |
| Form 6-K DR REDDYS LABORATORIES For: Sep 22 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.28% | |
| Form 6-K DR REDDYS LABORATORIES For: Sep 21 | SEC filing · Form 6-K | SEC EDGAR | +0.08% | -0.20% | |
| Form 6-K DR REDDYS LABORATORIES For: Sep 18 | SEC filing · Form 6-K | SEC EDGAR | +0.66% | +0.16% | |
| Form 6-K DR REDDYS LABORATORIES For: Sep 11 | SEC filing · Form 6-K | SEC EDGAR | -0.25% | -0.17% | |
| Form 6-K DR REDDYS LABORATORIES For: Sep 10 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 6-K DR REDDYS LABORATORIES For: Aug 26 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.08% | |
| Form 6-K DR REDDYS LABORATORIES For: Aug 14 | SEC filing · Form 6-K | SEC EDGAR | +0.49% | -0.41% | |
| Form 6-K DR REDDYS LABORATORIES For: Aug 13 | SEC filing · Form 6-K | SEC EDGAR | +0.12% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Dr. Reddy's Laboratories Limited (RDY) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.04% | +0.24% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Dr. Reddy's Laboratories Limited (RDY) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.00% | +0.04% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Dr. Reddy's Laboratories Limited (RDY) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.00% | — | |
| Form 6-K DR REDDYS LABORATORIES For: Aug 07 | SEC filing · Form 6-K | SEC EDGAR | +0.04% | — | |
| Dr. Reddy's Laboratories Limited (RDY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +0.16% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Dr. Reddy's Laboratories Limited (RDY) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.04% | -0.25% | |
| Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States | Press release | Business Wire | -0.41% | +0.33% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dr. Reddy's Laboratories Limited (RDY) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.04% | +0.37% | |
| Form 6-K DR REDDYS LABORATORIES For: Aug 01 | SEC filing · Form 6-K | SEC EDGAR | +1.04% | +0.83% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Dr. Reddy's Laboratories Limited (RDY) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.04% | +0.83% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Dr. Reddy's Laboratories Limited (RDY) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.04% | +0.30% | |
| Form 6-K DR REDDYS LABORATORIES For: Jul 28 | SEC filing · Form 6-K | SEC EDGAR | +0.21% | +0.09% | |
| Form 6-K DR REDDYS LABORATORIES For: Jul 29 | SEC filing · Form 6-K | SEC EDGAR | -0.08% | -0.34% | |
| Form 6-K DR REDDYS LABORATORIES For: Jul 23 | SEC filing · Form 6-K | SEC EDGAR | +4.12% | +3.51% | |
| Form 6-K DR REDDYS LABORATORIES For: Jul 22 | SEC filing · Form 6-K | SEC EDGAR | -0.17% | -5.17% | |
| Form 6-K DR REDDYS LABORATORIES For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.85% | |
| Form 6-K DR REDDYS LABORATORIES For: Jul 13 | SEC filing · Form 6-K | SEC EDGAR | +0.11% | -1.75% | |
| Form 6-K DR REDDYS LABORATORIES For: Jul 10 | SEC filing · Form 6-K | SEC EDGAR | -1.84% | -3.09% | |
| Form 6-K DR REDDYS LABORATORIES For: Jul 09 | SEC filing · Form 6-K | SEC EDGAR | +1.10% | +1.53% | |
| Form 6-K DR REDDYS LABORATORIES For: Jul 01 | SEC filing · Form 6-K | SEC EDGAR | +0.42% | -2.44% | |
| Form 6-K DR REDDYS LABORATORIES For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.42% | -2.44% | |
| Form 6-K DR REDDYS LABORATORIES For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.03% | -0.28% | |
| Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F | Press release | Business Wire | +0.16% | -1.38% | |
| Form 6-K DR REDDYS LABORATORIES For: Jun 25 | SEC filing · Form 6-K | SEC EDGAR | -0.13% | -1.31% | |
| Form 6-K DR REDDYS LABORATORIES For: Jun 19 | SEC filing · Form 6-K | SEC EDGAR | +1.48% | +3.04% | |
| Form 6-K DR REDDYS LABORATORIES For: Jun 20 | SEC filing · Form 6-K | SEC EDGAR | +1.48% | +3.04% | |
| Form 6-K DR REDDYS LABORATORIES For: Jun 22 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.11% | |
| Form 6-K DR REDDYS LABORATORIES For: Jun 13 | SEC filing · Form 6-K | SEC EDGAR | -0.22% | -0.45% | |
| Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States | Press release | Business Wire | -0.22% | -0.45% | |
| Form 6-K DR REDDYS LABORATORIES For: Jun 10 | SEC filing · Form 6-K | SEC EDGAR | -0.11% | -1.15% | |
| Form 6-K DR REDDYS LABORATORIES For: Jun 05 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.34% | |
| Form 6-K DR REDDYS LABORATORIES For: Jun 01 | SEC filing · Form 6-K | SEC EDGAR | -0.04% | -1.41% | |
| Form 6-K DR REDDYS LABORATORIES For: May 30 | SEC filing · Form 6-K | SEC EDGAR | -0.04% | -1.41% | |
| Form 20-F DR REDDYS LABORATORIES For: Mar 31 | SEC filing · Form 20-F | SEC EDGAR | -0.04% | -1.41% | |
| Form 6-K DR REDDYS LABORATORIES For: May 28 | SEC filing · Form 6-K | SEC EDGAR | -0.52% | -0.52% | |
| Form 6-K DR REDDYS LABORATORIES For: May 16 | SEC filing · Form 6-K | SEC EDGAR | +0.51% | -0.15% | |
| Form 6-K DR REDDYS LABORATORIES For: May 18 | SEC filing · Form 6-K | SEC EDGAR | -0.04% | +0.18% | |
| Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada | Press release | Business Wire | +0.51% | -0.15% | |
| Form 6-K DR REDDYS LABORATORIES For: May 15 | SEC filing · Form 6-K | SEC EDGAR | -0.07% | -0.07% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RDY section they belong to.
Where else RDY is measured.
RDY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OBALON THERAPEUTICS (OBLN) | 532 | -0.09% | 42% |
| Oncolytics Biotech Inc. - Common Shares (ONCY) | 530 | -0.06% | 43% |
| LOXO ONCOLOGY (LOXO) | 526 | 0.00% | 49% |
| Quest Diagnostics Incorporated (DGX) | 524 | +0.03% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Dr. Reddy's Laboratories Ltd's median reaction calculated?
Every labeled RDY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 528 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of RDY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RDY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.